Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PPBT 
Purple Biotech (PPBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PPBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $34
1 Year Target Price $34
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.09% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.20M USD | Price to earnings Ratio - | 1Y Target Price 34 |
Price to earnings Ratio - | 1Y Target Price 34 | ||
Volume (30-day avg) 1 | Beta -0.74 | 52 Weeks Range 2.00 - 10.20 | Updated Date 06/30/2025 |
52 Weeks Range 2.00 - 10.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 476.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.83% | Return on Equity (TTM) -12.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -554966 | Price to Sales(TTM) 58.08 |
Enterprise Value -554966 | Price to Sales(TTM) 58.08 | ||
Enterprise Value to Revenue 33.08 | Enterprise Value to EBITDA -0.15 | Shares Outstanding 2648200 | Shares Floating 520392142 |
Shares Outstanding 2648200 | Shares Floating 520392142 | ||
Percent Insiders 1.85 | Percent Institutions 1.79 |
Analyst Ratings
Rating 1 | Target Price 34 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Purple Biotech
Company Overview
History and Background
Purple Biotech Ltd., formerly Kitov Pharma Ltd., is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. Founded in 2010, the company has evolved through various acquisitions and strategic shifts, focusing on personalized cancer treatments.
Core Business Areas
- CM24: CM24 is a monoclonal antibody targeting CEACAM5, being developed for colorectal and pancreatic cancer. It aims to overcome resistance to chemotherapy and immunotherapy.
- NT219: NT219 is a small molecule inhibitor targeting IRS1/2 and STAT3, designed to disrupt tumor survival and proliferation pathways, being developed for solid tumors.
Leadership and Structure
The leadership team consists of experienced professionals in the biopharmaceutical industry. The company operates with a structure typical of a clinical-stage biotech, focusing on R&D, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- CM24: Monoclonal antibody targeting CEACAM5 for colorectal and pancreatic cancer. Currently in clinical development (Phase 1/2). Market share is currently zero as it is not yet commercialized. Competitors include companies developing similar antibodies or targeted therapies for these cancers, such as Eli Lilly (Gerdan), Amgen, Roche, and Bristol Myers Squibb.
- NT219: Small molecule inhibitor targeting IRS1/2 and STAT3 for solid tumors. Currently in clinical development (Phase 1/2). Market share is currently zero as it is not yet commercialized. Competitors include companies developing similar small molecule inhibitors or targeted therapies for these cancers, such as Novartis, Pfizer, and Merck.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The oncology segment is highly competitive and rapidly evolving, with increasing focus on personalized medicine and targeted therapies.
Positioning
Purple Biotech is positioned as a clinical-stage company developing novel therapies for unmet needs in oncology. Its competitive advantage lies in its innovative targeting mechanisms and potential to overcome drug resistance.
Total Addressable Market (TAM)
The global oncology market is estimated to be in the hundreds of billions of dollars. Purple Biotech is focusing on specific subsets of this market (colorectal, pancreatic, and other solid tumors), so their TAM is a smaller fraction, but still significant. They aim to become a major player within those niche markets.
Upturn SWOT Analysis
Strengths
- Novel targeting mechanisms (CEACAM5, IRS1/2, STAT3)
- Potential to overcome drug resistance
- Experienced management team
- Clinical-stage pipeline
Weaknesses
- High R&D costs
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- Currently no revenue-generating products
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new indications
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- LLY
- AMGN
- ROCHE
- BMY
Competitive Landscape
Purple Biotech faces significant competition from larger, more established pharmaceutical companies. Its success depends on demonstrating superior efficacy and safety compared to existing therapies and competing pipeline candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is marked by research progress and clinical trial initiation. The company's value is tied to its pipeline development.
Future Projections: Future growth is contingent on the success of CM24 and NT219 in clinical trials. Analyst estimates are dependent on this.
Recent Initiatives: Recent initiatives include advancing CM24 and NT219 through clinical trials, securing funding for research and development, and exploring potential partnerships.
Summary
Purple Biotech is a clinical-stage biopharmaceutical firm with promising cancer therapies in development, but it faces high financial risks and intense competition. The success of its CM24 and NT219 trials are critical. The company's novel mechanisms could offer a competitive edge if clinical results are positive. It needs to explore partnership opportunities to maintain its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports (Hypothetical)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Financial data is based on information available to date. Actual financial results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Purple Biotech
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-11-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://purple-biotech.com |
Full time employees 9 | Website https://purple-biotech.com | ||
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.